[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Impact in
- Journal
- PubMed
In The Last Decade
doi.org/w32084405 →Countries where authors are citing [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
This map shows the geographic impact of [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]. with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]. more than expected).
Fields of papers citing [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
This network shows the impact of [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]..
About [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
This paper, published in 2001, received 2.0k indexed citations . Written by Hans‐Henrik Parving, Hendrik Lehnert, Jens Brøchner‐Mortensen, Ramón Gomis, Steen Andersen and Peter Arner. It is primarily cited by scholars working on Cardiology and Cardiovascular Medicine (1.1k citations), Endocrinology, Diabetes and Metabolism (753 citations), Nephrology (739 citations), Pharmacology (157 citations) and Pulmonary and Respiratory Medicine (122 citations). Published in PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/w32084405.